CDEC's Updated Recommendations present Provincial/Territorial Advocacy Opportunities:
In June we reported that CADTH and the CDEC had updated their recommendations on the four curative HCV medicines that are currently approved in Canada for use on patients F0 and up, rather than F2 or higher - ie, fibrosis levels should not be an eligibility factor for treatment. (BTW, this is in line with AHC's Position paper released last November.)
As a follow up, we have sent some letters to the provinces and territories, (except BC, PEI and QC) letting them know about the update, as many provinces indicate that they use the CDEC recommendations to set their own formularies, and asking them when they plan to update their formularies from F2 to F0. We hope to be able to schedule meetings with some of them over the coming weeks to discuss this important policy change, which could really open up treatment eligibility in this country.
If you would like support in prepping a friendly MPP or MLA to raise this issue in your province, let us know, we would be happy to help.